PUMA BIOTECHNOLOGY, INC. (PBYI) Gross margin 2017–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) gross margin by fiscal year — reported gross profit divided by reported revenue.
74.5%FY2025 · since FY2017: 79.9% → 74.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 74.5% | +2.5 pp |
| FY2024 | 72.1% | -1.3 pp |
| FY2023 | 73.4% | -2.4 pp |
| FY2022 | 75.8% | +1.0 pp |
| FY2021 | 74.8% | -7.7 pp |
| FY2020 | 82.5% | -4.0 pp |
| FY2019 | 86.5% | +0.3 pp |
| FY2018 | 86.2% | +6.3 pp |
| FY2017 | 79.9% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Operating incomePBYI Operating marginPBYI Operating cash flowPBYI Free cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Total liabilitiesPBYI Shareholders’ equityPBYI overview →